C4 Therapeutics

57 articles with C4 Therapeutics

• C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

  6/21/2021

  – CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins.

• C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

  6/21/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the closing of an underwritten public offering of 4,887,500 shares of its common stock.

• C4 Therapeutics Announces Pricing of Public Offering

  6/16/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $37.00 per share.

• C4 Therapeutics Launches Proposed Public Offering

  6/14/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), today announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.

• C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

  6/14/2021

  C4 Therapeutics, Inc. announced that the first patient has been dosed in the Company’s clinical trial of CFT7455, an orally bioavailable MonoDAC™ targeting IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin’s lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

• C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

  6/7/2021

  Pre-clinical Data Support Plans to Advance CFT8919 to Clinical Development with IND Submission Expected in mid-2022 and Clinical Trial Initiation Expected by YE 2022

• C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies

  5/26/2021

  CFT8919 Pre-clinical Dataon EGFR L858R-driven NSCLC to be Presented at Keystone Symposium on Targeted Protein Degradation

• 

  C4 Therapeutics Aims to Launch EGFR L858R Degrader Into the Clinic in 2022

  5/26/2021

  The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.

• C4 Therapeutics Appoints Lauren White as Chief Financial Officer

  5/20/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the appointment of Lauren White to the role of chief financial officer, effective June 21, 2021. Ms. White’s appointment will initiate William (Bill) McKee’s planned transition from interim chief financial officer, a role he has held sin

• C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

  5/13/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today reported business highlights and financial results for the first quarter of 2021.

• C4 Therapeutics to Present at Upcoming Investor Conferences - May 12, 2021

  5/12/2021

  C4 Therapeutics, Inc., a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, announced that the Company will participate in the following upcoming investor conferences:

• C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021

  4/10/2021

  CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models

• C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results

  3/11/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today reported business highlights and financial results for the year ended December 31, 2020

• C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual Meeting

  3/10/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that a late-breaking abstract featuring preclinical data for CFT7455 has been selected for presentation at the first session of the American Association for Cancer Research (AACR) 2021 Annual Meeting

• C4 Therapeutics to Participate in Upcoming March Investor Conferences

  2/24/2021

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will participate in the following upcoming March investor conferences: Cowen 41 st Annual Health Care Conference on Wednesday, March 3, 2021 at 11:40 a.m. ET

• C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/7/2021

  C4 Therapeutics, Inc., a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET.

• C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022

  1/6/2021

  Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial Expected in 1H 2021

• C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

  12/17/2020

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes as part of the Russell quarterly update, effective December 21, 2020. The Russell 2000 ® Index measures the performance of the small cap segment of the U.

• C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx

  11/25/2020

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Evercore ISI 3rd Annual HealthCONx on Thursday, December 3, 2020 at 8:25 a.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the

• C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

  11/13/2020

  C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 8:30 a.m. ET. A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors se